Citadel Advisors
CPRX

Citadel Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Citadel Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$941K Buy
38,000
+26,400
+228% +$629K ﹤0.01% 7794
2025
Q4 		$271K Sell
11,600
-5,900
-34% -$131K ﹤0.01% 10374
2025
Q3 		$345K Sell
17,500
-4,900
-22% -$101K ﹤0.01% 10031
2025
Q2 		$486K Buy
22,400
+13,000
+138% +$307K ﹤0.01% 8699
2025
Q1 		$228K Sell
9,400
-2,300
-20% -$51.8K ﹤0.01% 10194
2024
Q4 		$244K Sell
11,700
-3,700
-24% -$79.5K ﹤0.01% 10084
2024
Q3 		$306K Buy
15,400
+8,800
+133% +$163K ﹤0.01% 9294
2024
Q2 		$102K Sell
6,600
-60,600
-90% -$943K ﹤0.01% 10885
2024
Q1 		$1.07M Buy
67,200
+46,200
+220% +$696K ﹤0.01% 6777
2023
Q4 		$353K Sell
21,000
-19,200
-48% -$262K ﹤0.01% 8821
2023
Q3 		$470K Buy
40,200
+7,700
+24% +$103K ﹤0.01% 8193
2023
Q2 		$437K Buy
32,500
+6,100
+23% +$87.8K ﹤0.01% 8230
2023
Q1 		$438K Sell
26,400
-24,800
-48% -$409K ﹤0.01% 8580
2022
Q4 		$952K Buy
51,200
+17,900
+54% +$276K ﹤0.01% 6913
2022
Q3 		$427K Buy
33,300
+14,200
+74% +$168K ﹤0.01% 8812
2022
Q2 		$134K Sell
19,100
-800
-4% -$5.87K ﹤0.01% 11096
2022
Q1 		$165K Buy
+19,900
New +$141K ﹤0.01% 11749
2021
Q4 		– Sell
-32,600
Closed -$173K – 13884
2021
Q3 		$173K Sell
32,600
-78,300
-71% -$428K ﹤0.01% 12180
2021
Q2 		$638K Buy
110,900
+80,800
+268% +$417K ﹤0.01% 9465
2021
Q1 		$139K Sell
30,100
-19,900
-40% -$79.1K ﹤0.01% 12136
2020
Q4 		$167K Buy
50,000
+37,800
+310% +$127K ﹤0.01% 9871
2020
Q3 		$36K Buy
12,200
+400
+3% +$1.56K ﹤0.01% 9707
2020
Q2 		$55K Sell
11,800
-11,600
-50% -$52.1K ﹤0.01% 9257
2020
Q1 		$90K Sell
23,400
-16,700
-42% -$68.5K ﹤0.01% 8696
2019
Q4 		$150K Sell
40,100
-3,000
-7% -$14K ﹤0.01% 8362
2019
Q3 		$229K Buy
43,100
+14,400
+50% +$76.7K ﹤0.01% 7976
2019
Q2 		$110K Buy
28,700
+15,400
+116% +$66.5K ﹤0.01% 8506
2019
Q1 		$68K Buy
+13,300
New +$39.1K ﹤0.01% 8701
2018
Q4 		– Sell
-24,000
Closed -$91K – 9180
2018
Q3 		$91K Buy
+24,000
New +$75.2K ﹤0.01% 8608
2017
Q4 		– Sell
-13,500
Closed -$34K – 8007
2017
Q3 		$34K Buy
+13,500
New +$37K ﹤0.01% 7263
2016
Q1 		– Sell
-5,300
Closed -$13K – 6930
2015
Q4 		$13K Buy
5,300
+2,600
+96% +$7.45K ﹤0.01% 8166
2015
Q3 		$8K Sell
2,700
-300
-10% -$1.29K ﹤0.01% 8528
2015
Q2 		$12K Sell
3,000
-1,200
-29% -$4.78K ﹤0.01% 8349
2015
Q1 		$18K Buy
4,200
+3,100
+282% +$11.2K ﹤0.01% 7978
2014
Q4 		$3K Sell
1,100
-28,400
-96% -$77.9K ﹤0.01% 8332
2014
Q3 		$98K Buy
29,500
+28,100
+2,007% +$73.4K ﹤0.01% 6428
2014
Q2 		$4K Buy
+1,400
New +$2.99K ﹤0.01% 7755
2014
Q1 		– Sell
-300
Closed -$1K – 7860
2013
Q4 		$1K Buy
+300
New +$606 ﹤0.01% 6935

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's CPRX Position: Q1 2026 in Review

Citadel Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 88% in Q1 2026, buying an estimated $6.49M and bringing the position to 581,093 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Citadel Advisors first reported a position in CPRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $17.8M in Q1 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Citadel Advisors held 581,093 shares of Catalyst Pharmaceutical worth $14.4M as of Q1 2026.
  • Citadel Advisors bought 272,622 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.49M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2736 holding.
  • Citadel Advisors first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 45 quarters since.
  • Citadel Advisors's Catalyst Pharmaceutical position peaked at $17.8M in Q1 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.